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No Artifact, Hepatitis E Is Emerging
To the Editor:
Wenzel et al. report a declining hepatitis E virus (HEV) anti-
body (anti-HEV) seroprevalence in 1,092 German sera obtained in
1996 and in 2011 and conclude that a recent increase of endemic
hepatitis E is an artifact caused by increased awareness.1 We also
reported a declining seroprevalence, testing 538 Dutch sera from
1988, 621 from 2000, and 5,239 from 2011; but, in addition, we
show that, recently, anti-HEV seroprevalence in young (largely
unexposed) adults increased significantly.2 In addition, the routine
screening for HEV RNA of Dutch blood donations, targeted for
solvent-detergent plasma production, in pools of 96, shows an
increasing incidence. In the first 6 months of screening (October
2012–March 2013), 7 of 19,191 donations (1:2,742) were found
to be confirmed HEV RNA positive. In the most recent 6 months
(April 2014–September 2014), 18 of 10,991 (1:611) donations
were found to be confirmed HEV RNA positive. Our data indicate
that HEV has returned and that HEV infections are increasing in
The Netherlands.
HANS L. ZAAIJER, M.D., PH.D.
Sanquin Blood Supply Foundation–Blood-borne Infections
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Reply:
We thank Professor Zaaijer for his comments on our study
“Decline in Hepatitis E Virus Antibody Prevalence in Southeastern
Germany, 1996-2011.”1
We reported a substantially lower hepatitis E virus (HEV) anti-
body (anti-HEV) prevalence in German sera from 2011, as com-
pared to 1996. We concluded that the increasing rate of notified
hepatitis E is likely a result of the improved awareness of the dis-
ease and not the emerging nature of hepatitis E.
Professor Zaaijer in his letter raised the interesting question
about the latest trends in hepatitis E prevalence. He refers to a
recent study from the Netherlands, which—in agreement with our
findings—demonstrates declining total anti-HEV rates in Dutch
sera during the past decades.2 But, in spite of that, a prevalence
increase by 5.7% was found in the age group of 18-21 years old
(7% in 1995 and 12.7% in 2011).
We would like to point out that we did not observe such an
effect in our study: The age group 20-29 years old showed a
13.7% reduction in anti-HEV prevalence (28% in 1996 and
14.3% in 2011), a finding consistent with all other age groups we
analyzed. However, we cannot exclude a potentially reversed trend
in Germany in the very recent past, given that our study was not
designed to investigate the seroprevalence development during the
very last years. It should be most interesting to address this
question in future studies also in Germany.
JU¨RGEN J. WENZEL, M.D.
WOLFGANG JILG, M.D.
Institute of Clinical Microbiology and Hygiene
University Medical Center Regensburg
Regensburg, Germany
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